恒瑞医药注射用SHR-A2009、阿得贝利单抗注射液获批临床试验

北京商报08-04

8月4日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，同意注射用SHR-A2009联合阿得贝利单抗、或联合三代EGFRTKI在非小细胞肺癌患者开展Ⅱ期临床试验。　　根据公告，注射用SHR-A2009是一款以HER3为靶点的抗体药物偶联物；阿得贝利单抗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656453263?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-04 18:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656453263","market":"sh","top_or_hot":-1,"title":"恒瑞医药注射用SHR-A2009、阿得贝利单抗注射液获批临床试验","media":"北京商报","content":"<div>\n<p>8月4日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，同意注射用SHR-A2009联合阿得贝利单抗、或联合三代EGFRTKI在非小细胞肺癌患者开展Ⅱ期临床试验。　　根据公告，注射用SHR-A2009是一款以HER3为靶点的抗体药物偶联物；阿得贝利单抗...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608043831311222.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药注射用SHR-A2009、阿得贝利单抗注射液获批临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药注射用SHR-A2009、阿得贝利单抗注射液获批临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-04 18:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608043831311222.html><strong>北京商报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月4日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，同意注射用SHR-A2009联合阿得贝利单抗、或联合三代EGFRTKI在非小细胞肺癌患者开展Ⅱ期临床试验。　　根据公告，注射用SHR-A2009是一款以HER3为靶点的抗体药物偶联物；阿得贝利单抗...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608043831311222.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608043831311222.html","article_id":"2656453263","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608043831311222.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656453263","pubTimestamp":1785838512,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"8月4日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，同意注射用SHR-A2009联合阿得贝利单抗、或联合三代EGFRTKI在非小细胞肺癌患者开展Ⅱ期临床试验。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","01276":"恒瑞医药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0012":"证金概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0183":"MSCI概念","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0188":"融资融券","MDTX":"Corgi MediaTek 2x Daily ETF","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","PSYK":"PSYK ETF","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","BMED":"iShares Health Innovation Active ETF","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK0196":"行业龙头","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK1191":"制药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0239":"医药制造","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H"},"translate_title":"Hengrui Medicine's SHR-A2009 for injection and adebelimab injection were approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5,"IBBJ":1.5,"IBBQ":1.5,"MDTX":1.5,"PSYK":1.5,"BMED":1.5},"content_text":"8月4日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，同意注射用SHR-A2009联合阿得贝利单抗、或联合三代EGFRTKI在非小细胞肺癌患者开展Ⅱ期临床试验。　　根据公告，注射用SHR-A2009是一款以HER3为靶点的抗体药物偶联物；阿得贝利单抗注射液是恒瑞医药自主研发的人源化抗PD-L1单克隆抗体，已获批两项适应症。（文章来源：北京商报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656453263","isCrawlerRequest":true}